Lacosamide Eg

Lacosamide, the active ingredient in Lacosamide Eg, is an anticonvulsant presented as an oral formulation for oral use. It treats partial‑onset seizures as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamide Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant used in the management of focal epileptic disorders.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. Adjunctive therapy for epilepsy: improves overall seizure control as part of combination therapy.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild gastrointestinal upset. - Headache: occasional throbbing pain. - Fatigue: feeling unusually tired. - Vision changes: blurred or double vision. - Tremor: mild shaking of limbs.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergent mood changes. - Hepatic dysfunction: elevated liver enzymes. - Respiratory depression: difficulty breathing in severe cases. - Allergic anaphylaxis: rapid onset of swelling, hives, or airway compromise.

Before initiating therapy, consider the following safety measures.

Renal impairment: adjust monitoring if kidney function is reduced. Cardiac disease: evaluate baseline ECG for PR‑interval abnormalities. Concomitant CNS depressants: monitor for additive sedation. Pregnancy and lactation: discuss potential risks with a healthcare professional. Alcohol consumption: avoid excessive intake as it may increase dizziness. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase lacosamide plasma levels. - Cardiac conduction drugs (e.g., class IA antiarrhythmics): risk of additive PR‑interval prolongation. - Other sodium‑channel blockers: heightened risk of CNS depression.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in hormonal efficacy. - Antidepressants (SSRIs, SNRIs): monitor for increased dizziness or somnolence. - Anticoagulants: observe for any changes in bleeding tendency.